Abstract 311P
Background
Thyroid cancer is the most common endocrine-related malignancy in the Philippines. It ranks seventh overall based on the latest Department of Health statistics. Its incidence increases every year, noted especially in females and in the reproductive age group. This study determined the incidence and the profile of all thyroid carcinomas encountered in a tertiary teaching hospital in the Philippines.
Methods
Data were collected from the University of Santo Tomas Hospital in 2015 to 2018 from different specialties, including the Pathology Department. All information gathered were kept confidential in respect to the data privacy act.
Results
A total of 1618 thyroid specimens were sent for histopathologic examination from 2015-2018 and 35.6% (n = 576) of these were malignant. Fine needle aspiration was the most frequent form of biopsy done. Eight hundred eighty patients underwent thyroidectomy and 43% (n = 378) of them had malignancy based on final histopathology. Eighty one percent (81%) were females and 19% were males. The most common type of malignancy was papillary thyroid carcinoma (74.6%), followed by papillary microcarcinoma (18.4%), follicular carcinoma (4.8%), anaplastic carcinoma (0.7%), squamous cell (0.7%) and poorly differentiated carcinoma (0.9%). The most frequent subtype of papillary carcinoma seen was the conventional type (31.7%). Majority of the patients had no extrathyroidal extension (41%), no lymphovascular invasion (38%), had clear margins (70%) and had no lymph node involvement (21%). Of the patients diagnosed with papillary and follicular carcinoma and papillary microcarcinoma, 30% underwent RAI in the same institution. There were 17 patients who underwent radiation therapy, mostly for palliative intent because of RAI-refractory disease. There was one case who underwent concurrent chemoradiation for anaplastic thyroid carcinoma.
Conclusions
This study showed that one-third of thyroid specimens received in the institution turned out to be malignant, with papillary carcinoma still the most frequent type. Total thyroidectomy is the most common form of curative surgery done.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract